A phase II study of adavosertib plus carboplatin in patients with TP53-mutant advanced ovarian cancer, either resistant or refractory to first-line platinum-based chemotherapy, demonstrated an encouraging overall response rate (ORR) of 43% [Table 1][77]. This evidence concerns the gene TP53 and ovarian carcinoma.